Generic Drugs to Face 100% Tariffs Under Trump's New Policy

President Donald Trump has announced a significant shift in U.S. trade policy regarding generic pharmaceuticals, revealing plans to impose substantial tariffs on these imported drugs. Starting August 1, 2028, generic medications imported into the United States will face a 100% tariff, a move intended to encourage domestic production.

In a statement on his social media platform, Truth Social, Trump detailed a phased approach to the tariffs. Initially, for a period of two years beginning August 1, 2026, imported generic drugs will continue to be subject to zero tariffs. However, this grace period will be followed by a 100% tariff for one year, escalating to 200% thereafter. This policy marks a departure from the previous exclusion of generic drugs from broader pharmaceutical tariffs announced in April.

The stated objective behind this policy is to incentivize pharmaceutical companies to establish or expand manufacturing facilities within the United States. Trump emphasized that this measure is designed to penalize companies that do not invest in U.S.-based production within the given timeframe. Existing tariffs on other pharmaceutical products will remain unchanged, indicating a targeted approach specifically aimed at reshaping the generic drug manufacturing landscape.